Biotechnology company Threshold Pharmaceuticals Inc (THLD) Wednesday reported promising results from the clinical trials of the Phase 1 study of TH-302 in patients with advanced leukemia conducted at MD Anderson's Cancer Center in Houston, Texas.
The company stated that Thirty-two patients with either acute myelogenous leukemia, or AML, or acute lymphoblastic leukemia, or ALL, have been enrolled in the trial.
Efficacy assessments have demonstrated TH-302 activity in multiple subjects with relapsed/refractory AML and ALL as evidenced by stabilization or reduction of bone marrow and peripheral blast counts.
Commenting on the results, Dr. Marina Konopleva, M.D., Associate Professor in the Department of Leukemia at MD Anderson Cancer Center, said, ""With the establishment of the MTD, we look forward to better defining the safety and efficacy of single agent TH-302 in patients with advanced leukemias."
For comments and feedback: editorial@rttnews.com